RxDoctor Payments Data

Sangwoo Lee, MD

Ophthalmology · New York, NYNPI 1164476404

Payments from drug & device makers

$3,661in general payments, 2019–2025

Across 141 payments — averaging $25.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$482
  • Novartis$473
  • Mallinckrodt Hospital Products Inc.$473
  • Boston Scientific$414
  • AbbVie$338
  • Regeneron Healthcare Solutions, Inc.$250
  • plus $1K from 18 others

What the payments were for

  • Travel & lodging$461%
  • Food & beverage$3,50096%
  • Education$1153%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,661 in reported general payments places this provider in the 70th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$345,162
Medicare patients
581
Services billed
3,250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine704$685,969
XiidraLifitegrast201$167,284
Cyclosporine102$33,355
LumiganBimatoprost20$10,048
Olopatadine Hcl92$4,719
Azelastine Hcl143$2,726
Prednisolone Acetate44$2,180
Bepotastine Besilate13$1,730
ErythromycinErythromycin Base155$1,627
Ketorolac Tromethamine41$919
Latanoprost125$800
MoxifloxacinMoxifloxacin Hcl18$437
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha26$304
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat35$303
Timolol Maleate30$245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$338$696,017724 claims
Bausch & Lomb Americas Inc.Xiidra$177$167,284201 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →